Exact Sciences Corporation
The company provides cancer screening and diagnostic test products globally.
They offer Cologuard, a non-invasive stool-based DNA test for colorectal cancer detection.
Other tests include Oncotype DX Breast Recurrence Score Test and Colon Recurrence Score Test.
OncoExTra Test is used for tumor profiling in patients with advanced cancer.
The company also offers Covid-19 testing services.
Pipeline products aim to enhance Cologuards performance and develop blood-based tests.
Exact Sciences Corporation was incorporated in 1995 and is headquartered in Wisconsin.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (100.00) is significantly higher than the sector mean (67.88).
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (71.04) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (4.08%) is significantly lower than the sector mean (7.40%).
- EV/EBITDA (362.07) is significantly higher than the sector mean (36.02).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- The Price to Free Cash Flow ratio (118.37) is significantly higher than the sector mean.
- EBITDA Margin (1.10%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 357.5 |
| Price/Free Cash Flow' | 116.5 |
| ROIC | 4.1% |
| Net Debt/EBITDA | 71.0 |